Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,026.55 USD
-1.12 (-0.11%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $1,023.00 -3.55 (-0.35%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1,026.55 USD
-1.12 (-0.11%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $1,023.00 -3.55 (-0.35%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Zacks News
Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura
by Zacks Equity Research
Ophthotech Corporation (OPHT) reported narrower-than-expected loss in the second quarter and also beat sales expectations.
Can Regeneron Pharma (REGN) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release second-quarter 2017 results on Aug 3 and we expect focus on Eylea's performance.
5 Top Multibagger Biotech Stocks to Buy in the 2nd Half
by Tirthankar Chakraborty
Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.
Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff
by Zacks Equity Research
Both stocks carry a Zacks Rank #2 (Buy).
Apple's Tim Cook earns $145M in 2016, Tops S&P 500 CEOs
by Zacks Equity Research
Apple Inc.'s (AAPL) Chief Executive Officer (CEO) Tim Cook has been declared the highest-paid CEO in the U.S., per a Bloomberg's report of take-home pay for the top 25 S&P 500 CEOs.
BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).
Roche (RHHBY) Launches Cobas Test for Bacterial Infections
by Zacks Equity Research
Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.
Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US
by Zacks Equity Research
Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.
Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label
by Zacks Equity Research
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.
Acorda Files NDA for Parkinson's Disease Candidate Inbrija
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.
Zacks.com featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group
by Zacks Equity Research
Zacks.com featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group
Sarepta Appoints Ex-Allergan Executive as CEO and President
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).
Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy
by Zacks Equity Research
The pharma and biotech industry has been blessed with good health in the first half of the year.
Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.
Neothetics' Fat Reduction Candidate Fails in Phase II Study
by Zacks Equity Research
Neothetics, Inc. (NEOT) announced disappointing top line results from a phase II proof-of-concept study, LIPO-202-CL-31, evaluating its lead candidate, LIPO-202, for reduction of submental subcutaneous fat.
Esperion's Combo Cholesterol Candidate Enters Phase III
by Zacks Equity Research
Esperion Therapeutics, Inc. (ESPR) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Zetia (10 mg) for an LDL-C lowering indication.
Teva/Xenon Nerve Pain Candidate Fails in Phase II Study
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that a mid-stage study evaluating their pipeline candidate, topical TV-45070 for post-herpetic neuralgia (PNH) did not meet the primary endpoint.
Strongbridge (SBBP) Shows Strength: Stock Moves Up 10.1%
by Zacks Equity Research
Strongbridge Biopharma plc (SBBP) moved big last session, as the company saw its shares rise over 10% on the day.
5 Biomedical Stocks That Are Expected To Surge
by Jeffrey Hymen
With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year. If you want to add some to your portfolio, check out these 5 biomedical stocks that are primed to skyrocket here.
Agios/Celgene's Leukemia Candidate Positive in Phase I/II
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) has announced a positive efficacy and safety data from the ongoing phase I/II study on experimental candidate IDHIFA (enasidenib) at an oral session at the European Hematology Association (EHA).
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.
Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion
by Zacks Equity Research
Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism
Conatus's PSC Candidate Gets Orphan Designation in the U.S.
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) announced FDA's grant of Orphan Drug Designation (ODD) to its pipeline candidate IDN-7314 for treatment of primary sclerosing cholangitis.
Novartis Cardiovascular Drug Positive, NSCLC Drug Approved
by Zacks Equity Research
Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.
Kamada Withdraws Inhaled AAT Marketing Application in EU
by Zacks Equity Research
Kamada Ltd.'s (KMDA) decided to withdraw the marketing authorization application (MAA) for its inhaled formulation of Alpha-1 Antitrypsin (AAT) in the EU.